{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:41:39Z","timestamp":1753882899060,"version":"3.41.2"},"reference-count":14,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medical Case Reports"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p> This is a case report of a 75-year-old immunocompromised male who developed encephalopathy while undergoing treatment for disseminated herpes zoster with peripheral nerve involvement. While his initial presentation involved primarily profound lower extremity weakness, he developed progressive confusion to the point of obtundation only after initiation of standard therapy with intravenous acyclovir. The evaluation of his altered mental status was largely unremarkable. It was only after his acyclovir was discontinued that his symptoms resolved and he returned to his baseline mental status. His presentation was most consistent with acyclovir-induced neurotoxicity, which can present in patients with renal impairment and those who are immunocompromised. <\/jats:p>","DOI":"10.1177\/2050313x20946518","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T06:45:27Z","timestamp":1597214727000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Acyclovir-induced neurotoxicity in an immunocompromised patient"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-2259","authenticated-orcid":false,"given":"Daniel","family":"Marks","sequence":"first","affiliation":[{"name":"School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6826-7332","authenticated-orcid":false,"given":"Andrew","family":"De La Paz","sequence":"additional","affiliation":[{"name":"Internal Medicine Residency Program, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bobbi Jo","family":"Walston","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"bibr1-2050313X20946518","unstructured":"Centers for Disease Control and Prevention. Shingles (herpes zoster): clinical overview, 2019, https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview.html"},{"key":"bibr2-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268801005921"},{"key":"bibr3-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674"},{"key":"bibr4-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70022-5"},{"key":"bibr5-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.2.147"},{"key":"bibr6-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02527.x"},{"key":"bibr7-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.9-6-630"},{"key":"bibr8-2050313X20946518","first-page":"114","volume":"32","author":"Ruiz-Roso G","year":"2012","journal-title":"Nefrologia"},{"key":"bibr9-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.911520"},{"key":"bibr10-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.03.001"},{"key":"bibr11-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg119"},{"key":"bibr12-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl067"},{"key":"bibr13-2050313X20946518","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13196"},{"key":"bibr14-2050313X20946518","unstructured":"Acyclovir sodium injection; United States prescribing information (revised May, 2014), http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=badf347b-eeee-4239-9c74-966f262925aa"}],"container-title":["SAGE Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X20946518","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X20946518","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X20946518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T21:45:46Z","timestamp":1737755146000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X20946518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":14,"alternative-id":["10.1177\/2050313X20946518"],"URL":"https:\/\/doi.org\/10.1177\/2050313x20946518","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"type":"print","value":"2050-313X"},{"type":"electronic","value":"2050-313X"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2050313X20946518"}}